Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Landos Biopharma Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
LABP
Nasdaq
8731
https://www.landosbiopharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Landos Biopharma Inc
Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs
- Mar 28th, 2024 1:50 pm
AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio
- Mar 26th, 2024 2:03 pm
Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday?
- Mar 25th, 2024 5:27 pm
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
- Mar 25th, 2024 12:31 pm
AbbVie to buy immune drug developer Landos
- Mar 25th, 2024 12:05 pm
Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results
- Mar 21st, 2024 12:00 pm
Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?
- Mar 5th, 2024 10:30 am
Landos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn’s and Colitis Organisation
- Jan 8th, 2024 1:00 pm
Landos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn’s and Colitis
- Nov 21st, 2023 1:00 pm
Landos Biopharma Provides Company Update and Reports Third Quarter 2023 Results
- Nov 9th, 2023 1:00 pm
Landos Biopharma to Present at the American College of Gastroenterology 2023 Annual Scientific Meeting
- Oct 23rd, 2023 12:00 pm
Landos Biopharma to Present New Data on NX-13 from Phase 1b Trial in Ulcerative Colitis at United European Gastroenterology (UEG) Week 2023 Congress
- Sep 19th, 2023 12:00 pm
Landos Biopharma Announces Strategic Research Collaboration with KU Leuven and University Hospitals Leuven to Further Characterize the Effects of NX-13 on Epithelial Cells
- Sep 14th, 2023 12:00 pm
Landos Biopharma Provides Business Update & Reports Second Quarter 2023 Results
- Aug 9th, 2023 12:00 pm
Landos Biopharma to Present at the 2023 Jefferies Healthcare Conference
- May 31st, 2023 8:15 pm
Landos Biopharma Expands Board of Directors with Appointment of Alka Batycky, Ph.D.
- May 30th, 2023 8:15 pm
Landos Biopharma Announces 1-for-10 Reverse Stock Split
- May 25th, 2023 8:05 pm
UPDATE -- Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results
- May 12th, 2023 12:50 pm
Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results
- May 12th, 2023 12:00 pm
Scroll